insights_auto
Why is LYEL down 8.57%?
Dive Deeperchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
$14.30
arrow_downward
-8.57%(-1.34) 1D
$14.30
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
$15.54
High
$15.76
Low
$14.20
Mkt. cap
456.64M
Avg. vol.
216.48K
Volume
236.66K
52-wk high
$45.00
52-wk low
$7.20
EPS
-$11.74
Beta
-0.04
Shares outstanding
24.59M
No. of employees
161
Open
$15.54
High
$15.76
Low
$14.20
Mkt. cap
456.64M
Avg. vol.
216.48K
Volume
236.66K
52-wk high
$45.00
52-wk low
$7.20
EPS
-$11.74
Beta
-0.04
Shares outstanding
24.59M
No. of employees
161
News stories
From web sources and news partners
GuruFocus
·
15 hours ago
LYEL Maintains Buy Rating -- Price Target Lowered to $39.00 by HC Wainwright
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitelyell.com